TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Streamlined Genetic Testing in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Diagnosed with metastatic prostate cancer or Gleason 7+ prostate cancer~* Diagnosed between 2010-2020~Exclusion Criteria:~* Age 81 or older~* Previous cancer genetic counseling or testing~* Previously scheduled for cancer genetic counseling or testing~* Cannot participate in English~* Are not capable of providing informed consent

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Proactive Streamlined Genetic Education and Testing (Type: EXPERIMENTAL): Participants randomized to this arm will proactively receive genetic education print materials and the option to proceed directly with genetic testing.
- Usual Care (Type: ACTIVE_COMPARATOR): Participants in this arm will be sent a referral letter recommending that they schedule a genetic counseling session and providing them with contact information to do so.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: European Study on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Children aged 3-8 years who attend the Preventive and Paediatric Department of Greifswald University, Germany.~(Lithuania: children who attend the paediatric dentistry department, Dental Faculty, Lithuanian University of Health Sciences)~* At least one primary molar tooth with caries into dentine involving two dental surfaces (diagnosed according to the International Caries Detection and Assessment System \[ICDAS\], codes 3 to 5)~* Willing to be examined~Exclusion Criteria:~* Clinical or radiographic signs of pulpal or peri-radicular pathology~* Patients with a systemic disease requiring special considerations during their dental treatment.~* Parents/children who refuse to participate in the study

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- Hall Technique (Type: EXPERIMENTAL): This technique uses preformed Stainless Steel Crowns (SSCs) to restore carious primary molars. Local anaesthesia, caries removal or tooth preparation are not required.
- Non-Restorative Caries Treatment (Type: EXPERIMENTAL): This is a less operative approach, here carious lesions are opened removing the overhanging enamel and making the cavity accessible for biofilm removal. No carious dentine will be removed from the pulpal wall and no local anaesthesia will be placed. Fluoride varnish (Duraphat ®) will be applied to the cavity. Parents/children will be trained to clean the cavity by brushing using a buccolingual technique.
- Conventional Restoration (Type: ACTIVE_COMPARATOR): This technique corresponds to the conventional way of treating cavitated carious lesions involving complete caries removal, use of local anaesthesia (when needed), and a compomer (Dyract ®) restoration. Cotton wool roll isolation and continuous aspiration will be used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluticasone Nasal Spray Patient Preference Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* allergic rhinitis~* literate~Exclusion Criteria:~* clinical significant uncontrolled disease~* Use of intranasal corticosteroids (\<4 weeks of FP \[branded or generic\],\<4 week exposure to FF, \<4 weeks use of other INS)~* Use of intranasal medications \<1 week~* Use of meds that significantly inhibit CYP4503A4~* Use of perfume or oral rinse on study day~* Allergy/intolerance to INS, antihistamines, or excipients~* Positive pregnancy test or female who is breastfeeding~* Affiliation with investigational site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fluticasone propionate (FP) (Type: ACTIVE_COMPARATOR): 200 micrograms (mcg); an aqueous suspension of microfine FP
- fluticasone furoate (FF) (Type: ACTIVE_COMPARATOR): 110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men \& women ≥20 years of age~* Unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer)~* Histologically confirmed adenocarcinoma~* Refractory to or intolerant of standard therapy~* ECOG Performance Status score 0 or 1~* A life expectancy of at least 3 months~Exclusion Criteria:~* Current or past history of severe hypersensitivity to any other antibody products~* Patients with multiple primary cancers~* Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment~* Patients with active, known or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ONO-4538 Arm (Type: EXPERIMENTAL): ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Placebo Arm (Type: PLACEBO_COMPARATOR): Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Registry of Treatment Adherence for Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients starting treatment with a new antipsychotic medication, in accordance with product labeling in the local country~* Permitted by their physician and by the patient to participate in a clinical trial~Exclusion Criteria:~* Patients not meeting all of the inclusion criteria for entry into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Two-year Study of Telbivudine in HBeAg Negative Hepatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Detectable serum HBsAg at the Screening visit and at least 6 months prior~* HBeAg negative at Screening visit~* serum HBV DNA level \>2,000 IU/mL at Screening visit~* Elevated serum ALT≥2 ×ULN and \<10×ULN at Screening visit (excluding ALT elevations due to non-HBV reasons such as drug, alcohol etc)~Exclusion Criteria:~* Patient has a history of clinical signs/symptoms of hepatic decompensation (Child-Pugh Grade B or C) or ascites, esophageal variceal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis.~* Patient has a history of hepatocellular carcinoma (HCC) or suspected symptoms of HCC, such as suspicious foci on imaging studies and/or serum alpha-fetoprotein (AFP)\>50ng/mL.~* Patient has received treatment of nucleoside or nucleotide drugs whether approved or investigational before.~* Patient has received IFN or other immunomodulatory treatment within 52 weeks before Screening.~* Patient has a medical condition that requires frequent use of systemic acyclovir or famciclovir.~* Patient has a medical condition that requires frequent use of systemic corticosteroids, however topical and inhaled corticosteroids are allowed.~* Patient has used hepatotoxic drugs within one month.~* Patient has overtaken alcohol (\>40g/day) or abused illicit drugs in recent one year.~* Use of other investigational drugs at the time of enrollment.~* History of hypersensitivity to any of the study drugs (telbivudine or adefovir).~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test.~* Patient is co-infected with HCV, HDV or HIV.~* Patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis).~* History of malignancy of any organ system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- HBeAg Negative Hepatitis (Type: EXPERIMENTAL): HBeAg Negative Hepatitis patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written Informed Consent~* Participants with Paget's disease randomized to the zoledronic acid arm from the CZOL446K2304 and CZOL446K2305 core studies and who were responders by 6 months~* Confirmed relapse of Paget's disease of bone (i.e., serum alkaline phosphatase (SAP) above upper limit of normal (ULN), bone scan, worsening clinical symptoms)~Exclusion Criteria:~* A participant previously treated with zoledronic acid who relapsed and was retreated with anti-resorptive bisphosphonate or calcitonin therapy within the last 12 months~* Bisphosphonate Hypersensitivity~* Participants with suspected/proven metastases at re-treatment~* Calculated creatinine clearance \<35 milliliter/minute (mL/min) at screening~* Serum calcium level \<2.07 millimole/liter (mmol/L) at screening~* Active primary hyperparathyroidism, hyperparathyroidism, hypoparathyroidism or hypothyroidism~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid 5 mg (Type: EXPERIMENTAL): Participants received single re-treatment dose of zoledronic acid 5 mg intravenous (IV) infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients signed the written informed consent~* The patients present with non-metastatic unilateral invasive ER-positive, HER2-negative breast cancer with a primary breast tumor \> 2cm by imaging or an axillary lymph node \> 2cm by imaging.~* Postmenopausal women with age less than 70 years old.~* The patients have no history of hormone therapy, chemotherapy, breast cancer surgery and radiotherapy.~* The patients have normal cardiac functions by echocardiography.~* The patients' ECOG scores are ≤2.~* The patients can swallow pills.~* The results of patients' blood tests are as follows:~  * Hb≥90g/L;~ * WBC≥4E+9/L;~ * Plt≥100E+9/L;~ * Neutrophils≥1.5E+9/L;~ * ALT and AST ≤ triple of normal upper limit;~ * TBIL ≤ 1.5 times of normal upper limit;~ * Creatinine ≤ 1.5 times of normal upper limit.~Exclusion Criteria:~* The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus;~* The patients have active infections that were not suitable for chemotherapy;~* The patients have severe non-cancerous diseases.~* The patients have bilateral breast cancers or multifocal breast cancers or inflammatory breast cancers.~* The patients have a history of previous treatment with mTOR inhibitors.~* The patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials.~* The patients are in some special conditions that they cannot understand the written informed consent, such as they are demented or hawkish.~* The patients have allergic history or contraindication of any of the interventional drugs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus+Letrozole (Type: EXPERIMENTAL): everolimus 10mg/d,po + letrozole 2.5mg/d,po \* 18 weeks
- Fluorouracil+epirubicin+cyclophosphamide (Type: ACTIVE_COMPARATOR): Fluorouracil 600mg/m2,iv,d1 + epirubicin 90mg/m2,iv,d1 + cyclophosphamide 600mg/m2,iv,d1 \* 6 cycles (every 21 days per cycle)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Resistance Training and Testosterone After Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male with Spinal Cord Injury~* Between 18-50 years old~* BMI \< 30 Kg/m2~* Traumatic motor complete C5-L2 level of injury~* American Spinal Injury Classification (A and B; i.e. motor deficit below the level of injury)~Exclusion Criteria:~* Cardiovascular disease~* Uncontrolled type II DM and those on insulin~* Pressures sores stage 2 or greater~* Supra-physiological T level~* Hematocrit above 50%~* Urinary tract infection or symptoms

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- RT+Tp (Type: EXPERIMENTAL): Resistance training using electrical stimulation and ankle weights and Testosterone patches
- Tp (Type: EXPERIMENTAL): Applying Testosterone patches

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* If female, cannot be of reproductive potential~* Have been treated with an optimal dose of statin for at least 6 weeks~* Coronary heart disease (CHD) or other atherosclerotic vascular disease with multiple risk factors (including diabetes, metabolic syndrome) and/or high LDL-C/low HDL-C, or needing to meet a specific LDL-C/HDL-C goal~Exclusion Criteria:~* Previously participated in a study with a cholesteryl ester transfer protein (CETP) inhibitor~* Homozygous familial hypercholesterolemia~* Severe chronic heart failure~* Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke within 3 months~* Uncontrolled hypertension~* Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins~* Active or chronic hepatobiliary, hepatic, or gall bladder disease~* History of mental instability, drug/alcohol abuse within the past five years or major psychiatric illness inadequately controlled and unstable~* History of ileal bypass, gastric bypass, or other significant condition associated with malabsorption~* Human immunodeficiency virus (HIV) positive~* History of malignancy ≤5 years~* Donated blood products or has had phlebotomy of \>300 mL within 8 weeks or intends to donate 250 mL of blood products or receive blood products within the projected duration of the study~* Currently taking medications that are potent inhibitors or inducers of cytochrome P450 3A4 (CYP3A) (including but not limited to cyclosporine, systemic itraconazole or ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St John's wort) or has discontinued treatment \<3 weeks prior~* Consumes more than 2 alcoholic drinks per day~* Currently participating or has participated in a study with an investigational compound or device within 3 months~* Receiving treatment with systemic corticosteroids or taking systemic anabolic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anacetrapib 100 mg (Type: EXPERIMENTAL): None
- Anacetrapib 25 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tapentadol (CG5503)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with osteoarthritis of the knee based on the American College of Rheumatology (ACR) criteria and functional capacity class of I-III~* patients taking analgesic medications for at least 3 months prior to screening and/or dissatisfied with their current therapy~* Patients requiring opioid treatment must be taking daily doses of opioid-based analgesic, equivalent to \<160 mg of oral morphine~* baseline score of greater than or equal to 5 on an 11-point numerical rating scale, calculated as the average pain intensity during the last 3 days prior to randomization.~Exclusion Criteria:~* History of alcohol and/or drug abuse in Investigator's judgement~* history of significant liver insufficiency~* chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past 3 months~* life-long history of seizure disorder or epilepsy~* history of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated~* uncontrolled hypertension~* patients with severely impaired renal function~* patients with moderate to severly impaired hepatic function or with laboratory values reflecting inadequate hepatic function

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks
- 002 (Type: ACTIVE_COMPARATOR): oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks
- 003 (Type: PLACEBO_COMPARATOR): placebo matching placebo twice a day (BID) during 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with Fanconi Anemia complementation group A (FA-A)~* Minimum age 1 year~* Maximum age 21 years~* Lansky Index\> 60%.~* Informed consent in accordance with current legal regulations.~* Number of cells to be transduced: At least 3x10\^5 purified CD34+ / kg body weight.~* Negative result in the urine pregnancy test at the baseline visit for women of childbearing age, who should be committed to using an effective contraceptive method during the period of study participation.~Exclusion Criteria:~* Patients with an human leukocyte antigen (HLA) identical family donor.~* Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities predicting the same in bone marrow aspirates. In this case, the studies carried out two months in advance of the patient's entry into the clinical trial will be considered valid.~* Evidence that the patient to be infused has signs of somatic mosaicism, with hematologic improvement.~* Any illness or concomitant process that in the opinion of the investigator incapacitates the subject for their participation in the study.~* Pre-existing sensory or motor impairment\> = grade 2 according to the National Cancer Institute (NCl) criteria.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Autologous CD34+ cells transducted with PGK-FANCA-Wpre * (Type: EXPERIMENTAL): CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre\*The product to be infused consist of a suspension of transduced CD34\^+ cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete